Delivery Order SPE2DB25D3504-SPE2DB25FVVTL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,313.71 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections. This competitively awarded, firm fixed price contract with no set-aside designation is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement to support federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $14,317.78 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Teriparatide 560mcg/2.24ml pen injections. This is a firm fixed-price, non-set-aside contract with a completion date of July 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Teriparatide is a recombinant human parathyroid hormone used primarily in the treatment of osteoporosis and bone-related conditions. This...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $16,561.84 for the supply of Teriparatide 560mcg/2.24ml pens. This firm fixed price, competitively awarded contract was issued by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, with an ultimate completion date of July 24, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Teriparatide 560mcg/2.24mL pen injections, with a contract ceiling value of $2,811.47 and an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $4,168.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Teriparatide 560mcg/2.24ml pens. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award is non-set-aside and was competitively awarded. Performance will be completed by July 25,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Teriparatide 600 mcg/2.4 mL pens. The contract has a ceiling value of $2,100.62 and a period of performance through September 5, 2024. It is a firm fixed-price contract, with no set-aside designation. This delivery order is likely part of a larger Indefinite Delivery Contract (IDC) vehicle between AmerisourceBergen and the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of 4,566,077,851 units of the pharmaceutical product Teriparatide 600 mcg/2.4 ml pen (2.4 ml). The contract has a ceiling value of $4,241.15 and a period of performance through October 11, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug teriparatide 560 mcg/2.24 ml pen in a 2.24 ml quantity. The contract has a firm fixed price of $3,167.44 and a completion date of May 22, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,717.33, is for the procurement of teriparatide 600 mcg/2.4 ml pens. The contract is a firm fixed-price delivery order, with an ultimate completion date of July 5, 2024. The contract is not designated as a set-aside and was competitively awarded. AmerisourceBergen holds a larger Indefinite...
- This is a $4,573.47 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Teriparatide 560mcg/2.24ml pens, a medication used to treat osteoporosis. The contract has an ultimate completion date of July 3, 2025 and is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB25FVVTLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,894.36 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. The contract, which was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which holds a potential value of $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military and federal healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a broad range of medications and medical supplies to support military healthcare programs and other government health systems. The company has demonstrated capability to meet federal procurement requirements through open competition, with its contract portfolio encompassing specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Teriparatide, a hormone treatment used primarily for osteoporosis management, aligns with the company's established role in supplying specialized pharmaceutical commodities to support defense healthcare missions worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 7/30/25 |